Thermo Fisher CEO trades 4,883 company shares
THERMO FISHER SCIENTIFIC INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
THERMO FISHER SCIENTIFIC INC. Chairman & CEO Marc N. Casper reported exercising options for 275 shares of common stock at an exercise price of $309.63 per share, leaving 20,275 option shares outstanding. On the same date, entities associated with him sold 4,883 common shares, through multiple open-market transactions at weighted average prices generally between $577.37 and $593.36 per share, including sales by Floral Park Associates, Inc. The trades were effected under a Rule 10b5-1 trading plan adopted on April 27, 2026. Indirect holdings include 5,000 shares held by MNC 2020 Irrevocable Trust and 11,300 shares held by Alison Casper 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except to any pecuniary interest.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
31 txns
Insider
CASPER MARC N
Role
Chairman & CEO
Sold
4,883 shs ($2.86M)
Approx. gross sale proceeds
$2.86M
Approx. exercise cost
$85K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F15 | 275 | $0.00 | $0.00 |
| Exercise | Common Stock | 275 | $309.63 | $85K |
| Sale | Common Stock F1 | 6 | $577.37 | $3K |
| Sale | Common Stock F1 | 4 | $579.26 | $2K |
| Sale | Common Stock F1 | 2 | $579.27 | $1K |
| Sale | Common Stock F1 | 4 | $580.71 | $2K |
| Sale | Common Stock F1 | 3 | $580.72 | $2K |
| Sale | Common Stock F1 | 5 | $581.85 | $3K |
| Sale | Common Stock F1 | 2 | $581.86 | $1K |
| Sale | Common Stock F1, F2 | 18 | $583.37 | $11K |
| Sale | Common Stock F1, F3 | 63 | $584.40 | $37K |
| Sale | Common Stock F1, F4 | 30 | $585.42 | $18K |
| Sale | Common Stock F1, F5 | 58 | $586.53 | $34K |
| Sale | Common Stock F1, F6 | 12 | $587.64 | $7K |
| Sale | Common Stock F1, F7 | 32 | $589.51 | $19K |
| Sale | Common Stock F1, F8 | 29 | $590.77 | $17K |
| Sale | Common Stock F1, F9 | 7 | $593.32 | $4K |
| Sale | Common Stock F1 | 94 | $577.37 | $54K |
| Sale | Common Stock F1, F10 | 114 | $579.26 | $66K |
| Sale | Common Stock F1, F11 | 113 | $580.71 | $66K |
| Sale | Common Stock F1, F12 | 113 | $581.85 | $66K |
| Sale | Common Stock F1, F13 | 302 | $583.35 | $176K |
| Sale | Common Stock F1, F3 | 1,035 | $584.41 | $605K |
| Sale | Common Stock F1, F4 | 530 | $585.44 | $310K |
| Sale | Common Stock F1, F5 | 945 | $586.52 | $554K |
| Sale | Common Stock F1, F6 | 228 | $587.64 | $134K |
| Sale | Common Stock F1, F7 | 522 | $589.52 | $308K |
| Sale | Common Stock F1, F8 | 495 | $590.78 | $292K |
| Sale | Common Stock F1, F9 | 117 | $593.31 | $69K |
| holding | Common Stock F14 | -- | -- | -- |
| holding | Common Stock F14 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,275 contracts (Direct);
Common Stock — 123,925.358 shares (Direct);
Common Stock — 0 shares (Indirect, By Floral Park Associates, Inc.);
Common Stock — 5,000 shares (Indirect, By MNC 2020 Irrevocable Trust);
Common Stock — 11,300 shares (Indirect, By Alison Casper 2020 Irrevocable Trust)
Footnotes (15)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive.
- F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive.
- F11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive.
- F12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive.
- F13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive.
- F14. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
- F15. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.
Key Figures
Options Exercised: 275 shares
Shares Sold: 4,883 shares
Sale Price Range: $583.01 to $593.36 per share
+4 more
7 metrics
Options Exercised
275 shares
Stock options exercised into common stock on 2026-08-07 at $309.63 per share
Shares Sold
4,883 shares
Total common shares sold across reported open-market transactions
Sale Price Range
$583.01 to $593.36 per share
Weighted average price ranges from multiple sale footnotes
Option Exercise Price
$309.63 per share
Exercise price of stock option converting into 275 common shares
Options Remaining
20,275 shares
Total option shares reported following the derivative exercise
MNC 2020 Trust Holding
5,000 shares
Indirect common stock holding by MNC 2020 Irrevocable Trust
Alison Casper 2020 Trust Holding
11,300 shares
Indirect common stock holding by Alison Casper 2020 Irrevocable Trust
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), indirectly beneficially owned
4 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
indirectly beneficially owned financial
"securities reported herein as indirectly beneficially owned"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Thermo Fisher (TMO) CEO Marc N. Casper report in this Form 4?
Marc N. Casper reported exercising options for 275 shares at an exercise price of $309.63 and selling 4,883 common shares in multiple open-market transactions, along with updated indirect trust holdings disclosures.
Were Marc N. Casper’s Thermo Fisher (TMO) trades under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Marc N. Casper on April 27, 2026, indicating the trades followed a pre-arranged trading schedule.
What Thermo Fisher (TMO) stock options does Marc N. Casper retain after this filing?
After exercising options for 275 shares, Marc N. Casper is reported as holding 20,275 option shares of Thermo Fisher common stock. The exercised option had a $309.63 per-share exercise price and expires on February 25, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates